RxDoctor Payments Data

Lorena Perez Povis, MD

Infectious Disease · San Angelo, TXNPI 1861601270

Payments from drug & device makers

$577in general payments, 2019–2025

Across 24 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$219
  • Astellas Pharma US Inc$150
  • Merck$115
  • Pfizer$36
  • Ferring Pharmaceuticals Inc.$27
  • Novo Nordisk$17
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$44677%
  • Education$13223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$577 in reported general payments places this provider in the 45th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$88,454
Medicare patients
232
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala204$809,195
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf35$172,387
TivicayDolutegravir Sodium67$153,965
GenvoyaElviteg/Cob/Emtri/Tenof Alafen28$113,981
DescovyEmtricitabine/Tenofov Alafenam42$95,993
TriumeqAbacavir/Dolutegravir/Lamivudi15$53,890
DovatoDolutegravir Sodium/Lamivudine14$48,295
Darunavir44$38,188
Daptomycin38$22,616
VemlidyTenofovir Alafenamide12$16,387
Oxacillin Sodium12$9,818
ErtapenemErtapenem Sodium24$7,799
Emtricitabine17$7,376
Cefepime Hcl29$5,874
Ritonavir39$4,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Triumeq, Dovato$219$256,14996 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 576 infectious disease providers in Texas.

Other infectious disease in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →